Drugs & Aging

, Volume 25, Issue 3, pp 187–196 | Cite as

Use of Gabapentin in the Treatment of Behavioural and Psychological Symptoms of Dementia

A Review of the Evidence
  • Yunie Kim
  • Kirsten M. Wilkins
  • Rajesh R. TampiEmail author
Leading Article


Behavioural and psychological symptoms of dementia (BPSD) have been defined as a heterogeneous range of psychological reactions, psychiatric symptoms and behaviours that may be unsafe, disruptive and impair the care of a patient in a given environment. To date, there are no US FDA-approved drugs or clear standards of pharmacological care for the treatment of BPSD. The novel antiepileptic agent gabapentin is being increasingly considered for use in the geriatric population because of its relatively favourable safety profile compared with other classes of psychiatric medications. Gabapentin has been administered to several geriatric patients with bipolar disorder and patients with dementia. It has also been reported to be successful in the treatment of a 13-year-old boy with behavioural dyscontrol, a finding that suggested a possible role for gabapentin in the treatment of other behavioural disorders. The purpose of this review was to find evidence for the use of gabapentin in the treatment of BPSD. To this end, a search was performed for case reports, case series, controlled trials and reviews of gabapentin in the treatment of this condition. The key words ‘dementia’, ‘Alzheimer’s disease’ and ‘gabapentin’ were used. Searches were performed in PubMed, PsycINFO, Ovid MEDLINE, Cochrane Library and The search revealed that there are limited data on the efficacy of gabapentin for BPSD in the form of 11 case reports, 3 case series and 1 retrospective chart review; no controlled studies appear to have been published to date on this topic. In most of the reviewed cases, gabapentin was reported to be a well tolerated and effective treatment for BPSD. However, two case reports in which gabapentin was used in the context of agitation in dementia with Lewy bodies questioned the appropriateness of gabapentin for all types of dementia-related agitation. The dearth of available data limits support for the off-label use of gabapentin for the treatment of BPSD. Furthermore, controlled studies should be conducted before gabapentin can be clinically indicated for the successful treatment of BPSD.


Dementia Risperidone Gabapentin Memantine Cholinesterase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This project is supported by funds from the Division of State, Community, and Public Health, the Bureau of Health Professions (BHPr), the Health Resources and Services Administration (HRSA), the Department of Health and Human Services (DHHS) under grant number 1 K01 HP 00071-03, and the Geriatric Academic Career Award. The information or content and conclusions are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by, the BHPr, HRSA, DHHS or the US Government. The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Bharucha AJ, Rosen J, Mulsant BH, et al. Assessment of behavioral and psychological symptoms of dementia. CNS Spectr 2002; 7(11): 797–802PubMedGoogle Scholar
  2. 2.
    Jackson-Siegal JM, Siegal AP. Improving elderly patient outcomes: anticonvulsants in agitation. Geriatrics 2002; 57(9): Suppl 5–8Google Scholar
  3. 3.
    Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293(5): 596–608PubMedCrossRefGoogle Scholar
  4. 4.
    Sommer BR, Fenn HH, Ketter TA. Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentin. Expert Opin Drug Saf 2007; 6(2): 133–45PubMedCrossRefGoogle Scholar
  5. 5.
    Moretti R, Torre P, Antonello RM, et al. Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation. Drugs Aging 2003; 20(14): 1035–40PubMedCrossRefGoogle Scholar
  6. 6.
    Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006; 355(15): 1525–38PubMedCrossRefGoogle Scholar
  7. 7.
    Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006; (1): CD003476Google Scholar
  8. 8.
    Tariot PN, Raman R, Jaimovich L, et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry 2005 Nov; 13(11): 942–9PubMedGoogle Scholar
  9. 9.
    Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001; 9(1): 58–66PubMedGoogle Scholar
  10. 10.
    Tariot PN, Schneider LS, Mintzer JE. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a doubleblind, placebo-controlled trial. CurrTher Res 2001 Jan; 62(1): 51–67Google Scholar
  11. 11.
    Sival RC, Haffmans PM, Jansen PA, et al. Sodium valproate in the treatment of aggressive behaviour in patients with dementia: a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 2002 Jun; 17(6): 579–85PubMedCrossRefGoogle Scholar
  12. 12.
    Porsteinsson AP. Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly. Drugs Aging 2006; 23(11): 877–86PubMedCrossRefGoogle Scholar
  13. 13.
    Tariot PN, Schneider LS, Katz IR. Anticonvulsant and other non-neuroleptic treatment of agitation in dementia. J Geriatr Psychiatry Neurol 1995; 8Suppl. 1: S28–39PubMedCrossRefGoogle Scholar
  14. 14.
    Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155(1): 54–61PubMedGoogle Scholar
  15. 15.
    Olin JT, Fox JS, Pawluczyk S, et al. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry 2001; 9(4): 400–5PubMedGoogle Scholar
  16. 16.
    Lanctot KL, Herrmann N, Rothenburg L, et al. GABAergic function in Alzheimer’s disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry 2004; 49(7): 439–53PubMedGoogle Scholar
  17. 17.
    Peskind ER, Tsuang DW, Bonner LT, et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis Assoc Disord 2005; 19(1): 23–8PubMedCrossRefGoogle Scholar
  18. 18.
    Mendez MF, Shapira JS, McMurtray A, et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 2007; 15(1): 84–7PubMedCrossRefGoogle Scholar
  19. 19.
    Garcia-Alloza M, Tsang SW, Gil-Bea FJ, et al. Involvement of the GABAergic system in depressive symptoms of Alzheimer’s disease. Neurobiol Aging 2006; 27(8): 1110–7PubMedCrossRefGoogle Scholar
  20. 20.
    Lanctot KL, Herrmann N, Rothenburg L, et al. Behavioral correlates of GABAergic disruption in Alzheimer’s disease. Int Psychogeriatr 2007; 19(1): 151–8PubMedCrossRefGoogle Scholar
  21. 21.
    FDA/CEDR. Neurontin: approval history, letters, reviews, and related documents [online]. Available from URL: [Accessed 2007 May 19]
  22. 22.
    Vieta E, Manuel Goikolea J, Martinez-Aran A, et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry 2006; 67(3): 473–7PubMedCrossRefGoogle Scholar
  23. 23.
    Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41(2): 119–28PubMedCrossRefGoogle Scholar
  24. 24.
    Choudhuri I, Sarvanathan N, Gottlob I. Survey of management of acquired nystagmus in the United Kingdom. Eye 2007; 21(9): 1194–7PubMedCrossRefGoogle Scholar
  25. 25.
    Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005; 366(9488): 818–24PubMedCrossRefGoogle Scholar
  26. 26.
    Reddy SY, Warner H, Guttuso Jr T, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006; 108(1): 41–8PubMedCrossRefGoogle Scholar
  27. 27.
    Gunal AI, Ozalp G, Yoldas TK, et al. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004; 19(12): 3137–9PubMedCrossRefGoogle Scholar
  28. 28.
    Manenti L, Vaglio A, Costantino E, et al. Gabapentin in the treatment of uremic itch: an index case and a pilot evaluation. J Nephrol 2005; 18(1): 86–91PubMedGoogle Scholar
  29. 29.
    Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?. Clin Pharmacokinet 2006; 45(11): 1061–75PubMedCrossRefGoogle Scholar
  30. 30.
    Parsons B, Tive L, Huang S. Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with post-herpetic neuralgia. Am J Geriatr Pharmacother 2004; 2(3): 157–62PubMedCrossRefGoogle Scholar
  31. 31.
    Laroche S. A new look at the second-generation antiepileptic drugs: a decade of experience. Neurologist 2007; 13(3): 133–9PubMedCrossRefGoogle Scholar
  32. 32.
    Bookwalter T, Gitlin M. Gabapentin-induced neurologic toxicities. Pharmacotherapy 2005; 25(12): 1817–9PubMedCrossRefGoogle Scholar
  33. 33.
    Parke-Davis. Neurontin (gabapentin) [package insert]. New York: Parke-Davis, 2005Google Scholar
  34. 34.
    Sethi MA, Mehta R, Devanand DP. Gabapentin in geriatric mania. J Geriatr Psychiatr Neurol 2003; 16(2): 117–20CrossRefGoogle Scholar
  35. 35.
    Robillard M, Conn D. Gabapentin use in geriatric patients with depression and bipolar illness [letter]. Can J Psychiatry 2001; 46(8): 764PubMedGoogle Scholar
  36. 36.
    Ryback R, Ryback L. Gabapentin for behavioral dyscontrol [letter]. Am J Psychiatry 1995; 152(9): 1399PubMedGoogle Scholar
  37. 37.
    Regan WM, Gordon SM. Gabapentin for behavioral agitation in Alzheimer’s disease. J Clin Psychopharmacol 1997; 17(1): 59–60PubMedCrossRefGoogle Scholar
  38. 38.
    Sheldon LJ, Ancill RJ, Holliday SG. Gabapentin in geriatric psychiatry patients. Can J Psychiatry 1998; 43(4): 422–3PubMedGoogle Scholar
  39. 39.
    Goldenberg G, Kahaner K, Basavaraju N, et al. Gabapentin for disruptive behaviour in an elderly demented patient. Drugs Aging 1998; 13(2): 183–4PubMedCrossRefGoogle Scholar
  40. 40.
    Low Jr RA, Brandes M. Gabapentin for the management of agitation. J Clin Psychopharmacol 1999 Oct; 19(5): 482–3PubMedCrossRefGoogle Scholar
  41. 41.
    Herrmann N, Lanctot K, Myszak M. Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. J Clin Psychopharmacol 2000; 20(1): 90–3PubMedCrossRefGoogle Scholar
  42. 42.
    Hawkins JW, Tinklenberg JR, Sheikh JI, et al. A retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementias. Am J Geriatr Psychiatry 2000; 8(3): 221–5PubMedGoogle Scholar
  43. 43.
    Dallocchio C, Buffa C, Mazzarello P. Combination of donepezil and gabapentin for behavioral disorders in Alzheimer’s disease [letter]. J Clin Psychiatry 2000 Jan; 61(1): 64PubMedCrossRefGoogle Scholar
  44. 44.
    Roane DM, Feinberg TE, Meckler L, et al. Treatment of dementia-associated agitation with gabapentin. J Neuropsychiatry Clin Neurosci 2000; 12(1): 40–3PubMedGoogle Scholar
  45. 45.
    Miller LJ. Gabapentin for treatment of behavioral and psychological symptoms of dementia. Ann Pharmacother 2001; 35(4): 427–31PubMedCrossRefGoogle Scholar
  46. 46.
    Moretti R, Torre P, Antonello RM, et al. Gabapentin as a possible treatment of behavioral alterations in Alzheimer disease (AD) patients. Eur J Neurol 2001; 8(5): 501–2PubMedCrossRefGoogle Scholar
  47. 47.
    Rossi P, Serrao M, Pozzessere G. Gabapentin-induced worsening of neuropsychiatric symptoms in dementia with Lewy bodies: case reports. Eur Neurol 2002; 47(1): 56–7PubMedCrossRefGoogle Scholar
  48. 48.
    Alkhalil C, Hahar N, Alkhalil B, et al. Can gabapentin be a safe alternative to hormonal therapy in the treatment of inappropriate sexual behavior in demented patients?. Int Urol Nephrol 2003; 35(2): 299–302PubMedCrossRefGoogle Scholar
  49. 49.
    Alkhalil C, Tanvir F, Alkhalil B, et al. Treatment of sexual disinhibition in dementia: case reports and review of the literature. Am J Ther 2004; 11(3): 231–5PubMedCrossRefGoogle Scholar
  50. 50.
    Raudino F, Mascalzi MG, Zagami A. Gabapentin and behavioral disorders in severe Alzheimer disease. J Clin Psychopharmacol 2004; 24(4): 459–60PubMedCrossRefGoogle Scholar
  51. 51.
    Department of Veterans Affairs. Specific interventions for agitation in Alzheimer’s disease. 2006 [online]. Available from URL: [Accessed 2008 Feb 5]
  52. 52.
    Dogukan A, Aygen B, Berilgen MS, et al. Gabapentin-induced coma in a patient with renal failure. Hemodial Int 2006; 10(2): 168–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Yunie Kim
    • 1
  • Kirsten M. Wilkins
    • 1
  • Rajesh R. Tampi
    • 1
    Email author
  1. 1.Department of PsychiatryYale University School of MedicineNew HavenUSA

Personalised recommendations